sufentanil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
opioid receptor agonists, analgesics, fentanyl derivatives	2491	56030-54-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: sulfentanyl sulfentanil sulfentanil citrate sufentanil sufentanil citrate	An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. Molecular weight: 386.55 Formula: C22H30N2O2S CLOGP: 3.59 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 32.78 ALOGS: -4.51 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

sulfentanyl
sulfentanil
sulfentanil citrate
sufentanil
sufentanil citrate

An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.

Molecular weight: 386.55
Formula: C22H30N2O2S
CLOGP: 3.59
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 32.78
ALOGS: -4.51
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	6 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.06 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	0 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	9.40 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	15 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.08 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	14 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
June 25, 2018	EMA	LABORATOIRE AGUETTANT
May 4, 1984	FDA	AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	1777.17	29.56	430	6640	23203	63458749
Hypotension	326.01	29.56	257	6813	272347	63209605
Bronchospasm	270.17	29.56	93	6977	17187	63464765
Anaphylactic reaction	231.68	29.56	123	6947	65977	63415975
Maternal exposure during delivery	179.42	29.56	40	7030	1460	63480492
Exposure during pregnancy	156.38	29.56	133	6937	155414	63326538
Cardiac arrest	142.72	29.56	102	6968	92443	63389509
Anaphylactoid shock	111.94	29.56	21	7049	316	63481636
Circulatory collapse	106.58	29.56	51	7019	21887	63460065
Tachycardia	106.44	29.56	95	6975	118061	63363891
Type I hypersensitivity	105.90	29.56	30	7040	2912	63479040
Acute generalised exanthematous pustulosis	100.42	29.56	40	7030	11059	63470893
Allergy test negative	95.55	29.56	17	7053	187	63481765
Cardio-respiratory arrest	92.13	29.56	66	7004	59893	63422059
Mixed liver injury	87.80	29.56	29	7041	4706	63477246
Shock	85.82	29.56	45	7025	23418	63458534
Respiratory depression	76.22	29.56	35	7035	13680	63468272
Oliguria	76.12	29.56	31	7039	9070	63472882
Eosinophilia	75.77	29.56	41	7029	22715	63459237
Multiple organ dysfunction syndrome	74.87	29.56	57	7013	56695	63425257
Bradycardia	74.18	29.56	63	7007	73164	63408788
Fatigue	71.36	29.56	8	7062	888020	62593932
Hepatocellular injury	71.32	29.56	42	7028	27339	63454613
Drug reaction with eosinophilia and systemic symptoms	70.50	29.56	45	7025	33791	63448161
Haemodynamic instability	69.06	29.56	29	7041	9161	63472791
Delayed recovery from anaesthesia	67.75	29.56	16	7054	755	63481197
Myoclonus	65.43	29.56	33	7037	15835	63466117
Rash maculo-papular	65.41	29.56	42	7028	31854	63450098
Ventricular fibrillation	65.05	29.56	30	7040	11837	63470115
Stress cardiomyopathy	64.98	29.56	28	7042	9422	63472530
Hepatorenal failure	64.12	29.56	15	7055	679	63481273
Toxic epidermal necrolysis	63.73	29.56	38	7032	25296	63456656
Peripheral nerve injury	59.29	29.56	13	7057	438	63481514
Anticholinergic syndrome	58.20	29.56	18	7052	2364	63479588
Spinal epidural haemorrhage	57.07	29.56	10	7060	100	63481852
Suspected product quality issue	55.96	29.56	11	7059	214	63481738
Hypocapnia	55.48	29.56	12	7058	379	63481573
Serotonin syndrome	52.06	29.56	35	7035	28647	63453305
Unwanted awareness during anaesthesia	51.50	29.56	11	7059	327	63481625
Carcinoid crisis	48.26	29.56	10	7060	256	63481696
Oxygen saturation decreased	47.80	29.56	54	7016	88531	63393421
Erythema	46.91	29.56	76	6994	175675	63306277
Vasoplegia syndrome	46.46	29.56	14	7056	1685	63480267
Patent ductus arteriosus	44.38	29.56	17	7053	4233	63477719
Metabolic acidosis	44.02	29.56	38	7032	45031	63436921
Spinal epidural haematoma	42.86	29.56	12	7058	1115	63480837
Stevens-Johnson syndrome	41.85	29.56	29	7041	24921	63457031
Myoglobin blood increased	40.25	29.56	12	7058	1393	63480559
Cholestasis	39.75	29.56	30	7040	29404	63452548
Hyperlactacidaemia	39.35	29.56	14	7056	2835	63479117
Paralysis	39.09	29.56	20	7050	9880	63472072
Dermatitis bullous	38.94	29.56	19	7051	8489	63473463
Mydriasis	38.28	29.56	21	7049	11935	63470017
Diarrhoea	38.27	29.56	16	7054	715350	62766602
Uterine hypotonus	37.20	29.56	7	7063	107	63481845
Epidural haemorrhage	36.45	29.56	7	7063	120	63481832
Anaesthetic complication	36.31	29.56	12	7058	1948	63480004
Postpartum haemorrhage	36.19	29.56	12	7058	1969	63479983
Torsade de pointes	36.12	29.56	21	7049	13330	63468622
Generalised tonic-clonic seizure	35.74	29.56	28	7042	28988	63452964
Sinus tachycardia	35.60	29.56	26	7044	24242	63457710
Cauda equina syndrome	35.07	29.56	10	7060	992	63480960
Hyperthermia	34.72	29.56	18	7052	9138	63472814
Post procedural stroke	34.71	29.56	6	7064	55	63481897
Altered state of consciousness	34.70	29.56	26	7044	25204	63456748
Acute pulmonary oedema	33.72	29.56	17	7053	8141	63473811
Posterior reversible encephalopathy syndrome	33.48	29.56	22	7048	17323	63464629
Foetal exposure during pregnancy	33.36	29.56	28	7042	31934	63450018
Reversal of opiate activity	32.41	29.56	4	7066	0	63481952
Premature baby	32.21	29.56	23	7047	20712	63461240
Foetal growth restriction	31.99	29.56	16	7054	7537	63474415
Suspected product contamination	31.56	29.56	5	7065	25	63481927
Angioedema	30.68	29.56	32	7038	47933	63434019
Cardiogenic shock	30.43	29.56	21	7049	17911	63464041
Haemodilution	30.04	29.56	6	7064	127	63481825
Foetal heart rate abnormal	29.88	29.56	8	7062	629	63481323

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	1151.54	30.58	300	5101	15641	34935889
Bronchospasm	190.35	30.58	69	5332	10662	34940868
Hyperthermia malignant	180.77	30.58	46	5355	2131	34949399
Hypotension	136.73	30.58	169	5232	221480	34730050
Anaphylactic reaction	133.69	30.58	75	5326	32226	34919304
Hypertransaminasaemia	114.31	30.58	40	5361	5566	34945964
Toxic epidermal necrolysis	111.11	30.58	58	5343	21588	34929942
Rash maculo-papular	109.45	30.58	63	5338	28388	34923142
Tachycardia	101.02	30.58	92	5309	84680	34866850
Eosinophilia	84.98	30.58	52	5349	26170	34925360
Circulatory collapse	84.67	30.58	48	5353	20990	34930540
Drug reaction with eosinophilia and systemic symptoms	83.52	30.58	56	5345	32956	34918574
Cholestasis	71.25	30.58	47	5354	26901	34924629
Haemodynamic instability	71.20	30.58	33	5368	9490	34942040
Erythema	64.78	30.58	74	5327	88706	34862824
Shock	61.09	30.58	41	5360	24138	34927392
Rhabdomyolysis	60.48	30.58	63	5338	68100	34883430
Type I hypersensitivity	58.18	30.58	17	5384	1322	34950208
Septic shock	56.00	30.58	62	5339	71772	34879758
Hepatic cytolysis	52.77	30.58	31	5370	14465	34937065
Injury	52.06	30.58	35	5366	20652	34930878
Allergy test negative	52.06	30.58	10	5391	121	34951409
Rash morbilliform	47.86	30.58	18	5383	3069	34948461
Delayed recovery from anaesthesia	47.65	30.58	13	5388	788	34950742
Cardiac arrest	47.52	30.58	66	5335	96093	34855437
Hepatorenal failure	47.16	30.58	12	5389	554	34950976
Victim of crime	46.55	30.58	11	5390	372	34951158
Anaphylactoid shock	46.41	30.58	11	5390	377	34951153
Multiple organ dysfunction syndrome	44.65	30.58	57	5344	76509	34875021
Stress cardiomyopathy	43.14	30.58	15	5386	2044	34949486
Hepatocellular injury	42.95	30.58	32	5369	22179	34929351
Patent ductus arteriosus	39.42	30.58	16	5385	3338	34948192
Mixed liver injury	38.27	30.58	15	5386	2858	34948672
Suspected product quality issue	38.12	30.58	8	5393	155	34951375
Suspected product contamination	37.39	30.58	7	5394	73	34951457
Infantile apnoea	36.52	30.58	11	5390	950	34950580
Post procedural haemorrhage	36.28	30.58	20	5381	8269	34943261
Coma	34.82	30.58	39	5362	45639	34905891
Fear	34.48	30.58	21	5380	10455	34941075
Bradycardia	33.16	30.58	49	5352	75369	34876161
Fibrinolysis increased	32.76	30.58	5	5396	12	34951518
Symmetrical drug-related intertriginous and flexural exanthema	31.88	30.58	8	5393	349	34951181
Acute generalised exanthematous pustulosis	31.46	30.58	17	5384	6759	34944771
Agitation neonatal	30.96	30.58	10	5391	1086	34950444
Diarrhoea	30.76	30.58	11	5390	389901	34561629
Anaesthetic complication	30.75	30.58	10	5391	1110	34950420

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic shock	2865.51	27.40	723	10912	35273	79697480
Bronchospasm	446.77	27.40	159	11476	24700	79708053
Anaphylactic reaction	361.61	27.40	196	11439	83547	79649206
Hypotension	318.04	27.40	354	11281	439963	79292790
Tachycardia	199.59	27.40	182	11453	177586	79555167
Hyperthermia malignant	193.63	27.40	51	11584	2866	79729887
Circulatory collapse	175.89	27.40	93	11542	37575	79695178
Cardiac arrest	169.71	27.40	164	11471	171932	79560821
Maternal exposure during delivery	167.62	27.40	39	11596	1307	79731446
Type I hypersensitivity	155.54	27.40	47	11588	4351	79728402
Toxic epidermal necrolysis	153.26	27.40	90	11545	44491	79688262
Rash maculo-papular	148.91	27.40	96	11539	55982	79676771
Drug reaction with eosinophilia and systemic symptoms	148.84	27.40	101	11534	64143	79668610
Anaphylactoid shock	142.94	27.40	31	11604	750	79732003
Eosinophilia	138.90	27.40	85	11550	45260	79687493
Allergy test negative	137.35	27.40	26	11609	308	79732445
Shock	136.90	27.40	83	11552	43465	79689288
Acute generalised exanthematous pustulosis	120.36	27.40	56	11579	17198	79715555
Mixed liver injury	111.94	27.40	42	11593	7536	79725217
Delayed recovery from anaesthesia	109.83	27.40	29	11606	1644	79731109
Hypertransaminasaemia	109.76	27.40	47	11588	11877	79720876
Hepatorenal failure	107.41	27.40	27	11608	1258	79731495
Erythema	106.13	27.40	146	11489	223144	79509609
Haemodynamic instability	104.70	27.40	51	11584	17331	79715422
Cholestasis	104.47	27.40	75	11560	52034	79680719
Hepatocellular injury	103.52	27.40	72	11563	47521	79685232
Fatigue	100.26	27.40	10	11625	929717	78803036
Stress cardiomyopathy	99.45	27.40	43	11592	11123	79721630
Multiple organ dysfunction syndrome	98.95	27.40	104	11531	120142	79612611
Suspected product quality issue	95.41	27.40	19	11616	298	79732455
Cardio-respiratory arrest	82.47	27.40	90	11545	108420	79624333
Respiratory depression	80.02	27.40	50	11585	27580	79705173
Bradycardia	77.28	27.40	97	11538	135460	79597293
Oliguria	72.51	27.40	39	11596	16270	79716483
Suspected product contamination	68.10	27.40	12	11623	92	79732661
Septic shock	67.02	27.40	86	11549	122715	79610038
Rash morbilliform	65.84	27.40	27	11608	6123	79726630
Rhabdomyolysis	65.57	27.40	78	11557	103053	79629700
Anaesthetic complication	61.73	27.40	21	11614	2838	79729915
Diarrhoea	59.80	27.40	27	11608	880462	78852291
Carcinoid crisis	59.05	27.40	14	11621	509	79732244
Hepatic cytolysis	56.51	27.40	40	11595	27111	79705642
Myoclonus	55.84	27.40	40	11595	27620	79705133
Acute pulmonary oedema	54.92	27.40	31	11604	14199	79718554
Dizziness	53.25	27.40	7	11628	526434	79206319
Torsade de pointes	51.06	27.40	33	11602	19279	79713474
Peripheral nerve injury	49.86	27.40	13	11622	701	79732052
Vasoplegia syndrome	49.57	27.40	19	11616	3611	79729142
Dermatitis bullous	49.55	27.40	29	11606	14216	79718537
Unwanted awareness during anaesthesia	48.93	27.40	11	11624	315	79732438
Symmetrical drug-related intertriginous and flexural exanthema	47.08	27.40	13	11622	873	79731880
Ventricular fibrillation	46.47	27.40	38	11597	31888	79700865
Hypocapnia	46.32	27.40	12	11623	631	79732122
Anticholinergic syndrome	46.10	27.40	18	11617	3593	79729160
Headache	45.98	27.40	19	11616	653753	79079000
Spinal epidural haemorrhage	44.96	27.40	9	11626	145	79732608
Exposure during pregnancy	44.77	27.40	64	11571	101068	79631685
Victim of crime	44.52	27.40	11	11624	477	79732276
Fibrinolysis increased	44.20	27.40	7	11628	25	79732728
Coma	43.53	27.40	63	11572	100586	79632167
Altered state of consciousness	43.51	27.40	42	11593	43780	79688973
Neuromuscular block prolonged	40.72	27.40	12	11623	1018	79731735
Fall	39.77	27.40	11	11624	487618	79245135
Oxygen saturation decreased	39.55	27.40	69	11566	128978	79603775
Respiratory acidosis	39.48	27.40	23	11612	11177	79721576
Ventricular tachycardia	39.40	27.40	39	11596	41896	79690857
Nervous system disorder	39.15	27.40	32	11603	26824	79705929
Hyperlactacidaemia	38.51	27.40	18	11617	5577	79727176
Fear	38.09	27.40	29	11606	21957	79710796
Arthralgia	38.01	27.40	18	11617	571785	79160968
Acute respiratory distress syndrome	37.78	27.40	39	11596	44028	79688725
Cardiogenic shock	37.58	27.40	38	11597	41876	79690877
Uterine hypotonus	36.97	27.40	7	11628	83	79732670
Spinal epidural haematoma	36.82	27.40	12	11623	1420	79731333
Anaesthetic complication neurological	36.77	27.40	10	11625	634	79732119
Postpartum haemorrhage	35.55	27.40	12	11623	1583	79731170
Tonic clonic movements	35.08	27.40	13	11622	2251	79730502
Malaise	34.79	27.40	14	11621	489855	79242898
Metabolic acidosis	33.29	27.40	50	11585	82479	79650274
Renal injury	33.07	27.40	24	11611	16903	79715850
Cauda equina syndrome	33.04	27.40	11	11624	1392	79731361
Anaphylactoid reaction	32.91	27.40	16	11619	5406	79727347
Haemodilution	32.86	27.40	7	11628	155	79732598
Device issue	32.76	27.40	29	11606	27079	79705674
Mydriasis	32.17	27.40	24	11611	17619	79715134
Urticaria	31.82	27.40	78	11557	185123	79547630
Foetal heart rate abnormal	31.75	27.40	8	11627	376	79732377
Hyperdynamic left ventricle	31.37	27.40	8	11627	395	79732358
Leukocytosis	31.17	27.40	35	11600	43420	79689333
Weight decreased	30.90	27.40	7	11628	355191	79377562
Epidural haemorrhage	30.54	27.40	7	11628	219	79732534
Weight increased	29.73	27.40	3	11632	277383	79455370
Post procedural stroke	29.35	27.40	6	11629	108	79732645
Angioedema	29.16	27.40	45	11590	75990	79656763
Cough	28.56	27.40	9	11626	366780	79365973
Nausea	28.40	27.40	61	11574	957135	78775618
Post procedural haemorrhage	28.02	27.40	20	11615	13724	79719029
Hypercapnia	27.97	27.40	17	11618	8918	79723835
Third stage postpartum haemorrhage	27.67	27.40	4	11631	6	79732747
Myoglobin blood increased	27.61	27.40	12	11623	3139	79729614

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N01AH03	NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Opioid anesthetics
CHEBI has role	CHEBI:35482	narcotic analgesic
CHEBI has role	CHEBI:38877	intravenous anesthetics
CHEBI has role	CHEBI:55322	mu-opioid agonists
CHEBI has role	CHEBI:60807	anaesthestic adjuvant
FDA MoA	N0000175684	Full Opioid Agonists
FDA EPC	N0000175690	Opioid Agonist
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000700	Analgesics
MeSH PA	D000701	Analgesics, Opioid
MeSH PA	D000777	Anesthetics
MeSH PA	D018686	Anesthetics, Intravenous
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D009294	Narcotics
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
General anesthesia	indication	50697003
Postoperative pain	indication	213299007
Asthenia	contraindication	13791008
Chronic disease of respiratory system	contraindication	17097001
Decreased cardiac function	contraindication	43650005
Bradycardia	contraindication	48867003
Injury of head	contraindication	82271004
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.37	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	10245228	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	10507180	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8226978	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8535714	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8778393	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8778394	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8865211	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	9320710	Jan. 5, 2027	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8202535	Oct. 22, 2030	TREATMENT OF ACUTE PAIN
EQ 0.03MG BASE	DSUVIA	VERTICAL PHARMS	N209128	Nov. 2, 2018	RX	TABLET	SUBLINGUAL	8865743	Oct. 22, 2030	TREATMENT OF ACUTE PAIN

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Mu-type opioid receptor	GPCR	P35372	OPRM_HUMAN	AGONIST	EC50	8.13	WOMBAT-PK	CHEMBL
Kappa-type opioid receptor	GPCR	P41145	OPRK_HUMAN		EC50	6.70	WOMBAT-PK
Delta-type opioid receptor	GPCR	P41143	OPRD_HUMAN		Ki	7.30	PDSP
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.71	CHEMBL
Mu-type opioid receptor	GPCR		OPRM_RAT		Ki	9.66	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane other		SGMR1_CAVPO		IC50	5.68	CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRM_RAT OPRK_RAT SGMR1_RAT		Ki	10.70	CHEMBL

External reference:

ID	Source
4019936	VUID
N0000148021	NUI
D00845	KEGG_DRUG
60561-17-3	SECONDARY_CAS_RN
4019269	VANDF
4019936	VANDF
C0143993	UMLSCUI
CHEBI:9316	CHEBI
CHEMBL658	ChEMBL_ID
DB00708	DRUGBANK_ID
CHEMBL1201163	ChEMBL_ID
D017409	MESH_DESCRIPTOR_UI
41693	PUBCHEM_CID
3534	IUPHAR_LIGAND_ID
4048	INN_ID
AFE2YW0IIZ	UNII
56795	RXNORM
10199	MMSL
32203	MMSL
5519	MMSL
d00378	MMSL
001570	NDDF
004630	NDDF
370275005	SNOMEDCT_US
37527009	SNOMEDCT_US
49998007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3382	INJECTION, SOLUTION	50 ug	EPIDURAL	ANDA	33 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3382	INJECTION, SOLUTION	50 ug	EPIDURAL	ANDA	33 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6110	INJECTION	0.05 mg	EPIDURAL	ANDA	27 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6111	INJECTION	0.05 mg	EPIDURAL	ANDA	27 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6112	INJECTION	0.05 mg	EPIDURAL	ANDA	27 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-050	INJECTION	50 ug	INTRAVENOUS	NDA	29 sections
Sufentanil Citrate	HUMAN PRESCRIPTION DRUG LABEL	1	17478-050	INJECTION	50 ug	INTRAVENOUS	NDA	29 sections
Dsuvia	Human Prescription Drug Label	1	61621-430	TABLET	30 ug	SUBLINGUAL	NDA	30 sections